BioSpace News Archive

Sonitor® Continues to Lead the Way in RTLS and IPS Demonstrating its flagship Sense ™ Ultrasound-based RTLS Technology at the Oracle Cerner Healthcare Conference in Booth #701.

UroGen Pharma to Host Thought Leader Webinar on UGN-102 and Non-Muscle Invasive Bladder Cancers.

NeuroPace, Inc today announced the first patient implanted in the NAUTILUS clinical study.

SCYNEXIS, Inc. (NASDAQ: SCYX) today announced that interim data from the Phase 3 FURI study of oral ibrexafungerp for the treatment of patients intolerant of, or with fungal disease refractory to, standard antifungal therapy will be presented during IDWeek 2022 being held in Washington, D.C October 19-23, 2022.

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”) today announced that 3D Medicines Inc., SELLAS’ licensee for the development and commercialization of its lead clinical candidate, galinpepimut-S (GPS), in China, Hong Kong, Macau and Taiwan, has dosed the first patient in its Phase 1 clinical trial in China of GPS (3D189 in China).

Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, announces the formation of Odyssey Neuropharma, Inc., a wholly owned subsidiary, focused on developing drugs to treat neurological disorders.

NorthStar Medical Radioisotopes, LLC and Eckert & Ziegler Isotope Technologies Dresden announced an agreement for the purchase of hot cells and related equipment for NorthStar’s dedicated non-carrier-added actinium-225 production facility.

BerGenBio ASA announced the initiation of a Phase 1b/2a trial evaluating bemcentinib in combination with the current standard of care, checkpoint inhibitor pembrolizumab and doublet chemotherapy, for the treatment of 1st line Non-Small Cell Lung Cancer patients harboring STK11 mutations.

IRRAS announced the launch of a new educational webinar series, ‘Exploring the Impact of IRRAflow’s Active Fluid Exchange: Our Early Experience Utilizing IRRAflow for Intracranial Hemorrhage’, with the Jacobs Institute.

Forge Biologics announced that Chief Medical Officer Maria Escolar, M.D, MS., will present updated clinical data from the RESKUE Phase 1/2 clinical trial for FBX-101—the Company’s novel gene therapy for the treatment of patients with Krabbe disease—during the 29th Congress of the European Society of Gene & Cell Therapy being held October 11-14, 2022, in Edinburgh, Scotland.